

BYD (1211 HK)

Our FY24 forecasts still on track post 1Q24

Maintain BUY. Although BYD's 1Q24 net profit of RMB 4.6bn missed our prior forecast on a massive R&D spending of RMB10.6bn, we believe the automaker is still on track to achieve our FY24E net profit forecast of RMB33bn. BYD's 1Q24 GPM also underscored our prior argument that its price cuts in Feb 2024 could be largely absorbed by cost reduction from suppliers. Nevertheless, we expect BYD to be more self-disciplined in SG&A and R&D expenses in the following quarters, should it put earnings at a higher priority.

- 1Q24 R&D beat our forecast.** BYD's 1Q24 revenue beat our prior forecast by 4%, largely due to BYDE. Its GPM was 1.3ppts higher than our estimates, which was offset by its larger-than-expected selling expenses. We did expect a possible wide range of 1Q24 net profit due to uncertainties from R&D expenses and impairment. These two expenses combined in 1Q24 were about RMB4.1bn higher than our estimates, as the R&D ratio reached 8.5% last quarter, the highest in history. The 1Q24 net profit would have been RMB6.9bn (vs. the actual RMB4.6bn), if the R&D ratio was the same as FY23 (6.6%), which would be in line with our prior net profit forecast.

- 20% sales volume growth in FY24 still achievable with resilient margins.** We are of the view that our FY24E sales volume forecast of 3.6mn units is still achievable, especially given the recent stimulus measures and overseas ramp-up. Such potential topline growth, along with the stimulus measures, could make its gross margin resilient, in our view. Even including its rising selling expenses, its 1Q24 margin (GPM-selling exp ratio) was close to that in 4Q23 when the sales volume was 51% higher (0.63mn units in 1Q24 vs. 0.94mn units in 4Q23). BYD's net profit per vehicle of RMB7,300 in 1Q24 was about RMB1,900 lower than that in 4Q23, while the automaker cut prices of most models by RMB20,000-30,000 in mid-Feb 2024.

- Earnings/Valuation.** It appears to us that BYD did not prioritize its 1Q24 earnings as it did not utilize its flexibility to lift its net profit amid its previous high earnings quality. We expect BYD to be more self-disciplined in SG&A and R&D expenses in the following quarters. We keep our FY24-25E net profit estimates largely unchanged, although we revise up both GPM and SG&A. Therefore, we maintain our BUY rating and target price of HK\$262, still based on 20x our FY24E EPS. Key risks to our rating and target price include lower sales and/or margins than expected, as well as a sector de-rating.

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	424,061	602,315	700,048	800,518	884,971
YoY growth (%)	96.2	42.0	16.2	14.4	10.5
Net profit (RMB mn)	16,622.4	30,040.8	33,108.6	40,173.1	45,095.3
YoY growth (%)	445.9	80.7	10.2	21.3	12.3
EPS (Reported) (RMB)	5.72	10.34	11.37	13.80	15.49
P/S (x)	1.4	1.0	0.8	0.7	0.7
P/E (x)	35.0	19.4	17.6	14.5	12.9
Yield (%)	0.6	1.5	1.1	1.4	1.5
ROE (%)	16.1	24.0	21.9	22.3	20.9
Net gearing (%)	(39.3)	(69.5)	(52.7)	(64.7)	(85.9)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price **HK\$262.00**

(Previous TP **HK\$262.00**)

Up/Downside **21.1%**

Current Price **HK\$216.40**

China Auto

Ji SHI, CFA

(852) 3761 8728

shiji@cmbi.com.hk

Wenjng DOU, CFA

(852) 6939 4751

douwenjing@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	629,971.3
Avg 3 mths t/o (HK\$ mn)	1,634.7
52w High/Low (HK\$)	275.60/171.70
Total Issued Shares (mn)	2911.1

Source: FactSet

Shareholding Structure

Mr. Wang Chuanfu	17.6%
Mr. Lv Xiangyang	8.2%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	7.3%	0.0%
3-mth	16.3%	5.3%
6-mth	-12.0%	-13.7%

Source: FactSet

12-mth Price Performance



Source: FactSet

Related Report

["BYD \(1211 HK\) - Good FY23 earnings quality" - 28 Mar 2024](#)

Figure 1: Quarterly results

RMB mn	1Q23	2Q23	3Q23	4Q23	1Q24	YoY	QoQ
Sales volume (units)	552,076	703,561	824,001	944,779	626,263	13.4%	-33.7%
Revenue	120,174	139,951	162,151	180,041	124,944	4.0%	-30.6%
Gross profit	21,467	26,206	35,876	38,209	27,341	27.4%	-28.4%
R&D expenses	(6,238)	(7,597)	(11,104)	(14,637)	(10,611)	70.1%	-27.5%
SG&A expenses	(8,014)	(9,643)	(9,851)	(11,166)	(10,572)	31.9%	-5.3%
Operating profit	5,299	8,433	12,906	11,466	5,798	9.4%	-49.4%
Net profit	4,130	6,824	10,413	8,674	4,569	10.6%	-47.3%
Gross margin	17.9%	18.7%	22.1%	21.2%	21.9%	4.0 ppt	0.7 ppt
Operating margin	4.4%	6.0%	8.0%	6.4%	4.6%	0.2 ppt	-1.7 ppt
Net margin	3.4%	4.9%	6.4%	4.8%	3.7%	0.2 ppt	-1.2 ppt

Source: Company data, CMBIGM

Figure 2: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	700,048	800,518	884,971	703,735	804,613	N/A	-0.5%	-0.5%	N/A
Gross profit	140,565	156,428	170,656	137,810	55,367	N/A	2.0%	0.7%	N/A
Operating profit	41,816	50,717	56,961	41,711	50,955	N/A	0.3%	-0.5%	N/A
Net profit	33,109	40,173	45,095	33,031	40,402	N/A	0.2%	-0.6%	N/A
Gross margin	20.1%	19.5%	19.3%	19.6%	19.3%	N/A	0.5 ppt	0.2 ppt	N/A
Operating margin	6.0%	6.3%	6.4%	5.9%	6.3%	N/A	0.0 ppt	0.0 ppt	N/A
Net margin	4.7%	5.0%	5.1%	4.7%	5.0%	N/A	0.0 ppt	0.0 ppt	N/A

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	700,048	800,518	884,971	753,238	895,188	984,337	-7.1%	-10.6%	-10.1%
Gross profit	140,565	156,428	170,656	146,806	175,457	192,005	-4.3%	-10.8%	-11.1%
Operating profit	41,816	50,717	56,961	43,181	54,246	57,064	-3.2%	-6.5%	-0.2%
Net profit	33,109	40,173	45,095	35,808	44,224	47,725	-7.5%	-9.2%	-5.5%
Gross margin	20.1%	19.5%	19.3%	19.5%	19.6%	19.5%	0.6 ppt	-0.1 ppt	-0.2 ppt
Operating margin	6.0%	6.3%	6.4%	5.7%	6.1%	5.8%	0.2 ppt	0.3 ppt	0.6 ppt
Net margin	4.7%	5.0%	5.1%	4.8%	4.9%	4.8%	0.0 ppt	0.1 ppt	0.2 ppt

Source: Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	216,142	424,061	602,315	700,048	800,518	884,971
Cost of goods sold	(187,998)	(351,816)	(480,558)	(559,484)	(644,090)	(714,315)
Gross profit	28,145	72,245	121,757	140,565	156,428	170,656
Operating expenses	(22,818)	(50,990)	(88,598)	(102,584)	(110,951)	(120,272)
Selling expense	(6,082)	(15,061)	(25,211)	(29,984)	(33,681)	(35,996)
Admin expense	(5,710)	(10,007)	(13,462)	(15,806)	(16,885)	(18,138)
R&D expense	(7,991)	(18,654)	(39,575)	(44,745)	(46,075)	(50,350)
Others	(3,035)	(7,267)	(10,350)	(12,049)	(14,310)	(15,788)
Operating profit	5,327	21,255	33,159	37,981	45,477	50,384
Other income	2,608	2,248	5,965	5,700	5,700	5,700
Other expense	(452)	(989)	(1,546)	(1,500)	(1,550)	(1,600)
Gain/loss on financial assets at FVTPL	47	126	258	45	45	45
Investment gain/loss	(57)	(792)	1,635	1,808	1,908	1,908
Other gains/(losses)	(1,168)	(2,387)	(3,677)	(4,063)	(3,530)	(3,902)
EBITDA	20,542	42,766	82,649	102,833	122,527	136,993
Depreciation	10,880	14,605	37,718	52,233	62,873	70,713
Depreciation of ROU assets	273	584	1,390	2,211	2,373	2,535
Other amortisation	2,956	5,181	4,444	5,282	5,852	6,396
EBIT	6,433	22,396	39,096	43,108	51,429	57,349
Interest income	632	1,830	2,796	3,136	3,379	4,815
Interest expense	(1,915)	(1,316)	(1,828)	(2,092)	(1,562)	(1,288)
Net Interest income/(expense)	(1,787)	1,618	1,475	1,045	1,817	3,527
Foreign exchange gain/loss	(533)	1,216	639	0	0	0
Pre-tax profit	4,518	21,080	37,269	41,016	49,867	56,061
Income tax	(551)	(3,367)	(5,925)	(6,282)	(7,600)	(8,495)
After tax profit	3,967	17,713	31,344	34,734	42,267	47,566
Minority interest	(922)	(1,091)	(1,303)	(1,626)	(2,094)	(2,471)
Net profit	3,045	16,622	30,041	33,109	40,173	45,095
Gross dividends	306	3,325	9,012	6,622	8,035	9,019

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	166,110	240,804	302,121	330,527	404,084	503,565
Cash & equivalents	49,820	51,182	108,512	99,000	140,389	214,258
Restricted cash	637	289	583	1,000	1,000	1,000
Account receivables	44,994	51,723	67,431	80,784	93,518	103,384
Inventories	43,355	79,107	87,677	99,634	114,701	127,207
Prepayment	2,037	8,224	2,215	11,190	12,882	14,286
Financial assets at FVTPL	5,606	20,627	9,563	9,613	9,663	9,713
Other current assets	11,168	16,099	23,481	25,317	27,370	28,675
Contract assets	8,493	13,553	2,660	3,989	4,562	5,043
Non-current assets	129,670	253,057	377,426	426,632	433,867	434,613
PP&E	61,221	131,880	230,904	284,673	289,803	287,093
Right-of-use assets	1,573	3,137	9,679	8,398	6,956	5,351
Deferred income tax	1,913	3,687	6,584	6,584	6,584	6,584
Investment in JVs & assos	7,905	15,485	17,647	19,847	22,047	24,247
Intangibles	17,105	23,223	37,236	39,996	41,338	42,383
Goodwill	66	66	4,428	4,428	4,428	4,428
Financial assets at FVTPL	234	2,147	2,696	2,791	2,886	2,981
Other non-current assets	39,652	73,431	68,252	59,914	59,825	61,545
Total assets	295,780	493,861	679,548	757,159	837,951	938,178
Current liabilities	171,304	333,345	453,667	502,152	546,654	605,263
Short-term borrowings	10,204	5,153	18,323	9,464	0	0
Account payables	73,160	140,437	194,430	230,461	256,754	284,747
Tax payable	1,779	4,326	7,852	9,197	10,588	11,742
Other current liabilities	71,227	147,911	198,363	199,381	226,374	250,063
Contract liabilities	14,934	35,517	34,699	53,649	52,939	58,711
Non-current liabilities	20,232	39,126	75,419	78,575	79,183	81,278
Long-term borrowings	8,744	7,594	11,975	11,975	10,975	9,975
Bond payables	2,046	0	0	1,000	2,000	3,000
Other non-current liabilities	9,442	31,533	63,444	65,599	66,207	68,303
Total liabilities	191,536	372,471	529,086	580,727	625,837	686,541

Share capital	2,911	2,911	2,911	2,911	2,911	2,911
Other reserves	92,159	108,118	135,899	160,395	194,147	231,407
Total shareholders equity	95,070	111,029	138,810	163,306	197,058	234,318
Minority interest	9,175	10,361	11,652	13,125	15,057	17,319
Total equity and liabilities	295,780	493,861	679,548	757,159	837,951	938,178

CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	4,518	21,080	37,269	41,016	49,867	56,061
Depreciation & amortization	14,108	20,370	43,553	59,725	71,098	79,643
Change in working capital	44,083	97,849	91,094	12,049	19,680	28,590
Others	2,757	1,539	(2,190)	2,731	(2,103)	(1,899)
Net cash from operations	65,467	140,838	169,725	115,522	138,542	162,396
Investing						
Capital expenditure	(37,344)	(97,457)	(122,094)	(98,955)	(68,025)	(68,250)
Acquisition of subsidiaries/ investments	(3,527)	(10,573)	(16,163)	(1,100)	(1,100)	(1,100)
Net proceeds from disposal of short-term investments	0	14	0	0	0	0
Others	(4,534)	(12,580)	12,593	(5,680)	(7,580)	(7,580)
Net cash from investing	(45,404)	(120,596)	(125,664)	(105,735)	(76,705)	(76,930)
Financing						
Dividend paid	(423)	(306)	(3,325)	(9,012)	(6,622)	(8,035)
Net borrowings	(17,006)	(16,413)	18,073	(4,106)	(9,464)	0
Proceeds from share issues	37,314	0	0	0	0	0
Others	(3,821)	(2,770)	(1,931)	(6,180)	(4,362)	(3,562)
Net cash from financing	16,063	(19,489)	12,817	(19,298)	(20,448)	(11,597)
Net change in cash						
Cash at the beginning of the year	13,738	49,820	51,182	108,512	99,000	140,389
Exchange difference	(44)	610	451	0	0	0
Cash at the end of the year	49,820	51,182	108,512	99,000	140,389	214,258

GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Revenue	38.0%	96.2%	42.0%	16.2%	14.4%	10.5%
Gross profit	(7.3%)	156.7%	68.5%	15.4%	11.3%	9.1%
Operating profit	(53.1%)	299.0%	56.0%	14.5%	19.7%	10.8%
EBITDA	(9.0%)	108.2%	93.3%	24.4%	19.2%	11.8%
EBIT	(36.0%)	248.1%	74.6%	10.3%	19.3%	11.5%
Net profit	(28.1%)	445.9%	80.7%	10.2%	21.3%	12.3%

PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Gross profit margin	13.0%	17.0%	20.2%	20.1%	19.5%	19.3%
Operating margin	2.5%	5.0%	5.5%	5.4%	5.7%	5.7%
EBITDA margin	9.5%	10.1%	13.7%	14.7%	15.3%	15.5%
Return on equity (ROE)	4.0%	16.1%	24.0%	21.9%	22.3%	20.9%

GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Net debt to equity (x)	(0.4)	(0.4)	(0.7)	(0.5)	(0.6)	(0.9)
Current ratio (x)	1.0	0.7	0.7	0.7	0.7	0.8
Receivable turnover days	94.4	58.1	52.0	52.0	52.0	52.0
Inventory turnover days	84.2	82.1	66.6	65.0	65.0	65.0
Payable turnover days	156.3	149.2	150.8	155.0	150.0	150.0

VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/E	187.7	35.0	19.4	17.6	14.5	12.9
P/B	6.0	5.2	4.2	3.6	3.0	2.5
P/CFPS	8.7	4.1	3.4	5.0	4.2	3.6
Div yield (%)	0.1	0.6	1.5	1.1	1.4	1.5

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.